Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Oct 27, 2023
Politics, Policy & Law

Oct. 27 Quick Takes: AbbVie pegs IRA cost at $2.1 billion

Plus: FDA approves Coherus’ PD-1 mAb based on China data, and updates from Otsuka, Sernova, Lilly, Roche and more
BioCentury | Feb 2, 2023
Regulation

Feb. 1 Quick Takes: FDA approves GSK’s daprodustat

Plus: Patient Square caps first fund at $3.9B, and updates from Verily-Otsuka Novartis, Evelo, Sherlock-Sense, Recurv and more
BioCentury | Mar 7, 2017
Company News

Neurovance, Otsuka deal

BioCentury | Mar 3, 2017
Company News

Otsuka acquiring ADHD company Neurovance

BioCentury | Aug 1, 2016
Clinical News

Centanafadine SR: Phase IIb data

BioCentury | Jan 18, 2016
Clinical News

Centanafadine SR: Phase IIb started

BioCentury | Feb 2, 2015
Emerging Company Profile

Three's company

How the serotonin component of Neurovance's ADHD candidate could set it apart
BioCentury | Jan 5, 2015
Clinical News

Centanafadine: Clinical trial data

Items per page:
1 - 8 of 8